CGRP monoklonální protilátky v léčbě migrény - indikační kritéria a terapeutická doporučení pro Českou republiku.

Current prophylactic treatment of frequent episodic and chronic migraine is often unsuccessful or associated with adverse events. Calcitonin gene-related peptide (CGRP) is a key peripheral and central patophysiological agent in migraine. Data emerging from trials with monoclonal antibodies suggest that specific blockade of the CGRP pathway may provide an effective and treatment in migraine. At present, precise indication criteria for the administration of these antibodies, required duration of their administration and methods of evaluating their effect, especially on the quality of life, are being determined. [ABSTRACT FROM AUTHOR]